Abstract
This article summarizes the findings of research aimed at comparing the effectiveness of anticoagulants in patients with atrial fibrillation and concomitant conditions, including heart failure. The studies evaluated the impact of warfarin, aspirin, dabigatran, edoxaban, and rivaroxaban on the risk of stroke, systemic embolisms, and bleeding events. The results indicate significant differences in the efficacy and safety of these medications: warfarin reduces the risk of stroke but increases the likelihood of bleeding; edoxaban and rivaroxaban showed a decrease in bleeding risk while maintaining efficacy in stroke prevention. The research also identified the stability of drug effects based on the severity of heart failure, emphasizing the need for an individualized approach to treatment selection in this patient group.